Imunon Inc (IMNN)
$1.01
+0.01
(+1.5%)▲
Performance
- $1.01$1.02$1.01
0.0%
Downside
Day's Volatility :0.98%
Upside
0.98%
- $0.48$3.65$1.01
52.48%
Downside
52 Weeks Volatility :86.85%
Upside
72.33%
Returns
| Period | Imunon Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -25.37% | 0.0% |
6 Months | -35.48% | 0.0% |
1 Year | -0.99% | 0.0% |
3 Years | -45.36% | -20.8% |
Highlights
Market Capitalization | 14.4M |
Book Value | $0.4 |
Earnings Per Share (EPS) | -1.91 |
Wall Street Target Price | 14.2 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -64.75% |
Return On Equity TTM | -143.19% |
Revenue TTM | 125.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 500.0K |
EBITDA | -19.6M |
Diluted Eps TTM | -1.91 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.77 |
EPS Estimate Next Year | -1.09 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.46 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1305.94%
Technicals Summary
Sell
Neutral
Buy
Imunon Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Imunon Inc | -6.54% | -35.48% | -0.99% | -45.36% | -45.36% |
 Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
 Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
 Alnylam Pharmaceuticals, Inc. | 7.12% | 73.95% | 61.12% | 32.59% | 252.19% |
 Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Imunon Inc | NA | NA | NA | -1.77 | -1.43 | -0.65 | NA | 0.4 |
Regeneron Pharmaceuticals, Inc. | 26.59 | 26.59 | 1.37 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.73 | 39.73 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Imunon Inc | Buy | $14.4M | -45.36% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.8B | 245.65% | 26.59 | 32.04% |
Novo Nordisk A/s | Buy | $522.1B | 354.53% | 39.73 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $118.5B | 172.0% | 32.84 | -4.74% |
Insights on Imunon Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 125.0K → 7.05M (in $), with an average increase of 98.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -4.92M → -4.78M (in $), with an average increase of 3.0% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 62.1%
Institutional Holdings
Renaissance Technologies Corp
0.77%Geode Capital Management, LLC
0.52%BlackRock Inc
0.40%Vanguard Group Inc
0.34%The Colony Group LLC
0.24%State Street Corp
0.15%
Company Information
celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.
Organization | Imunon Inc |
Employees | 33 |
CEO | Mr. Michael H. Tardugno |
Industry | Miscellaneous |
Discover More
Virios Therapeutics Inc
$1.01
+1.5%
Schwab International Dividend Equity Etf
$1.01
+1.5%
Allianzim Us Equity Buffer15 Uncapped Sep Etf
$1.01
+1.5%
Flexshares Quality Dividend
$1.01
+1.5%
Clene Inc
$1.01
+1.5%
Farmmi Inc
$1.01
+1.5%
Anfield Us Equity Sector Rotation Etf
$1.01
+1.5%
Graniteshares 2x Long Baba Daily Etf
$1.01
+1.5%
Stone Ridge 2055 Longevity Income Etf
$1.01
+1.5%